# An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients

> **NCT06284226** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Beijing Kejing Biotechnology Co., Ltd.**

## Conditions studied

- Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)

## Interventions

- **DRUG:** Allogeneic NK（CCT-ANK-11)

## Key facts

- **NCT ID:** NCT06284226
- **Lead sponsor:** Beijing Kejing Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-03-25
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The project is terminated
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06284226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06284226, "An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06284226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*